Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | EP300 | Q09472 | 1/20 | 0.30 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.30 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4079599 | 0.97 | ALDH1A1 (0.31) | ALDH1A1SMN1; SMN2NPSR1TSHRCYP2C19 | |
| SCHEMBL2192555 | 0.97 | TSHR (0.36) | ALDH1A1SMN1; SMN2NPSR1TSHRCYP2C19 | |
| Hydrochloric Acid SCHEMBL11579187 | 0.95 | TSHR (0.34) | ALDH1A1SMN1; SMN2NPSR1TSHRCYP2C19 | |
| SCHEMBL19392125 | 0.95 | — | — | |
| Hydrochloric Acid SCHEMBL27994742 | 0.92 | ALDH1A1 (0.30) | ALDH1A1TSHR | |
| SCHEMBL27869033 | 0.89 | — | — | |
| Hydrochloric Acid SCHEMBL16666609 | 0.86 | — | — | |
| SCHEMBL14677216 | 0.81 | — | — | |
| SCHEMBL28027738 | 0.80 | — | — | |
| SCHEMBL3164465 | 0.79 | TSHR (0.37) | TSHRCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 288 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12612624-B2 | Light-inducible CRISPR/Cas9 system for genome editing | THE JOHNS HOPKINS UNIVERSITY (US) | 2026-04-28 | — | — | US | disclosed |
| US-12404312-B2 | Engineered VEGF variants for retinal neuroprotection, promotion of axon growth and axon regeneration | MASSACHUSETTS EYE AND EAR INFIRMARY (US) | 2025-09-02 | — | — | US | disclosed |
| US-20250250562-A1 | TAT-INDUCED CRISPR/ENDONUCLEASE-BASED GENE EDITING | UNIV TEMPLE (US) | 2025-08-07 | — | — | US | disclosed |
| US-12377162-B2 | Anti-serine protease inhibitor kazal (SPIK) antibodies, immunoconjugates, and methods of use | IMCARE BIOTECH, LLC (US) | 2025-08-05 | — | — | US | disclosed |
| US-12357704-B2 | Tailored hypoimmune nanovesicular delivery systems for cancer tumors | Malcolm, Thomas (US) | 2025-07-15 | — | — | US | disclosed |
| EP-4522193-A2 | METHODS FOR TREATING AND/OR PREVENTING UNDESIRABLE SEQULAE OF NASAL TURBINOPLASTY OR FUNCTIONAL ENDOSCOPIC SINUS SURGERY | 3-D Matrix Ltd. (JP) | 2025-03-19 | — | — | EP | disclosed |
| US-12251429-B2 | Methods and compositions for RNA-guided treatment of HIV infection | Temple University—Of the Commonwealth System of Higher Education (US) | 2025-03-18 | — | — | US | disclosed |
| US-20250082778-A1 | RNA GUIDED ERADICATION OF HUMAN JC VIRUS AND OTHER POLYOMAVIRUSES | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2025-03-13 | — | — | US | disclosed |
| WO-2025019820-A1 | ALL IN ONE VECTORS FOR THE TREATMENT OF FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY | NEVADA RESEARCH & INNOVATION CORPORATION (US) | 2025-01-23 | — | — | WO | disclosed |
| US-20250001014-A1 | BAG3 COMPOSITIONS AND METHODS | TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2025-01-02 | — | — | US | disclosed |
| WO-2008134544-A1 | COMPOSITIONS FOR PREVENTION OF ADHESIONS AND OTHER BARRIER APPLICATIONS | ARCH THERAPEUTICS, INC. (US) | 2008-11-06 | — | — | WO | disclosed |
| WO-2008113030-A2 | TREATMENT OF LEAKY OR DAMAGED TIGHT JUNCTIONS AND ENHANCING EXTRACELLULAR MATRIX | ARCH THERAPEUTICS, INC (US) | 2008-09-18 | — | — | WO | disclosed |
| WO-2008100966-A1 | GDNF-DERIVED PEPTIDES | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2008-08-21 | — | — | WO | disclosed |
| CN-101247804-A | chemical compound | SMITHKLINE BEECHAM CORP (US) | 2008-08-20 | — | — | CN | disclosed |
| US-20080032934-A1 | COMPOSITIONS FOR PREVENTION OF ADHESIONS AND OTHER BARRIER APPLICATIONS | CLEAR NANO SOLUTIONS | 2008-02-07 | — | — | US | disclosed |
| EP-1879606-A1 | COMPOSITIONS AND METHODS FOR PROMOTING HEMOSTASIS AND OTHER PHYSIOLOGICAL ACTIVITIES | Massachussets Institute of Technology (US) | 2008-01-23 | — | — | EP | disclosed |
| US-20070203062-A1 | Compositions and methods for promoting hemostasis and other physiological activities | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-08-30 | — | — | US | disclosed |
| WO-2006116524-A1 | COMPOSITIONS AND METHODS FOR PROMOTING HEMOSTASIS AND OTHER PHYSIOLOGICAL ACTIVITIES | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2006-11-02 | — | — | WO | disclosed |
| US-4217238-A | BASIC SALT, SCRUBBING | EXXON RESEARCH & ENGINEERING CO. (US) | 1980-08-12 | — | — | US | disclosed |
| US-4094957-A | CARBON DIOXIDE | EXXON RESEARCH & ENGINEERING CO. (US) | 1978-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12612624-B2 | Light-inducible CRISPR/Cas9 system for genome editing | RNMT, AMPD2, NT5C2 | ALDH1A1 4025/4885SMN1; SMN2 922/4885NPSR1 3044/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.